Dichloroacetate

ApprovedSmall molecule

SSaol Therapeutics Inc

Dichloroacetate is one of 305 small molecule programs targeting Insulin resistance. It is currently in Approved.

Indications

Total Trials

Active Trials

304

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

ToxicityActive, not recruiting

Brain CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

GlioblastomaActive, not recruiting

Type 1 DiabetesActive, not recruiting

EndometriosisActive, not recruiting

Lactic AcidosisActive, not recruiting

HypoxiaActive, not recruiting

Glioblastoma MultiformeActive, not recruiting

Insulin ResistanceApproved

Active, not recruiting

ToxicityPreclinical

Active, not recruiting

Brain CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

Type 1 DiabetesPhase 1

Active, not recruiting

EndometriosisPreclinical

Active, not recruiting

Lactic AcidosisPreclinical

Active, not recruiting

HypoxiaPhase 1

Active, not recruiting

Glioblastoma MultiformePhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Dichloroacetate

SSaol Therapeutics Inc

Approved

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Imjudo

AstraZeneca

Preclinical

5 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Remeron

OOrganon and Co

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

Treatment

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Glioblastoma Multiforme

NCT05120284

Clinical

Trials by Indication[1]

Glioblastoma2 trials

Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma

Withdrawn·AAHS Cancer Control Alberta·Phase 1·NCT00703859

Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors

Completed·UUniversity of Florida·Phase 1·NCT01111097·15 enrolled

Type 1 Diabetes2 trials

Regulation of Brain Glucose Metabolism in Type 1 Diabetes

Recruiting·YYale University·Phase 1·NCT05317455·16 enrolled

Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes

Completed·YYale University·Phase 1·NCT03356457·21 enrolled

Solid Tumours1 trial

A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours

Completed·AAHS Cancer Control Alberta·Phase 1·NCT00566410·23 enrolled

Effectiveness1 trial

Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome

Unknown status·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00068913·35 enrolled

Insulin resistance1 trial

Role of Preoperative Carbohydrates Drinks, Dichloroacetate and Exercise on Postoperative Muscle Insulin Resistance

Unknown status·UUniversity of Nottingham·Phase 4·NCT02469337·40 enrolled

13 more indications

Trial1 trial

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

Active, not recruiting·SSaol Therapeutics Inc·Phase 3·NCT02616484·34 enrolled

Pilot Study1 trial

A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers

Completed·UUniversity of Florida·Phase 1·NCT02690285·45 enrolled

Endometriosis1 trial

A Clinical Trial to Evaluate Dichloroacetate (DCA) as a Treatment for Endometriosis-associated Pain

Completed·UUniversity of Edinburgh·N/A·NCT04046081·30 enrolled

Treatment1 trial

Expanded Access Treatment Protocol With DCA for Patients With PDCD

Available·SSaol Therapeutics Inc··NCT06931262

Brain Cancer1 trial

The Safety and Efficacy of DCA for the Treatment of Brain Cancer

Completed·UUniversity of Alberta·Phase 2·NCT00540176·40 enrolled

Non-Small Cell Lung Cancer1 trial

Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)

Terminated·JJonsson Comprehensive Cancer Center·Phase 2·NCT01029925·7 enrolled

Recurrent Head and Neck Cancer1 trial

Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers

Completed·—·Phase 1·NCT01163487·17 enrolled

Lactic Acidosis1 trial

Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Expanded Access

No longer available·UUniversity of Florida··NCT01797276

Metabolism1 trial

Dichloroacetate Kinetics, Metabolism and Toxicology

Completed·NNational Institute of Environmental Health Sciences (NIEHS)··NCT00015015·100 enrolled

Toxicity1 trial

Prevention of Dichloroacetate Toxicity

Completed·UUniversity of Florida·N/A·NCT00031161·30 enrolled

Hypoxia1 trial

Imaging and Biomarkers of Hypoxia in Solid Tumors

Terminated·SStanford University·Phase 1·NCT01123005·28 enrolled

Glioblastoma Multiforme1 trial

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

Active, not recruiting·UUniversity of Florida·Phase 2·NCT05120284·40 enrolled

Unspecified2 trials

Pharmacotoxicology of Trichloroethylene Metabolites

Terminated·UUniversity of Florida·N/A·NCT00865514·2 enrolled

Pharmacotoxicology of Trichloroethylene Metabolites

Completed·UUniversity of Florida·N/A·NCT00874276·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for Dichloroacetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dichloroacetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dichloroacetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Saol Therapeutics Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSaol Therapeutics Inc

Dichloroacetate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Glioblastoma2 trials

Type 1 Diabetes2 trials

Solid Tumours1 trial

Effectiveness1 trial

Insulin resistance1 trial

Trial1 trial

Pilot Study1 trial

Endometriosis1 trial

Treatment1 trial

Brain Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Recurrent Head and Neck Cancer1 trial

Lactic Acidosis1 trial

Metabolism1 trial

Toxicity1 trial

Hypoxia1 trial

Glioblastoma Multiforme1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News